Action 300558 BETTA PHARMACEUTICALS CO., LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Betta Pharmaceuticals Co., Ltd.

Actions

300558

CNE100002DD9

Cours en clôture Shenzhen S.E.
Autres places de cotation
 00:00:00 30/04/2024 		Varia. 5j. Varia. 1 janv.
41,73 CNY +0,34% Graphique intraday de Betta Pharmaceuticals Co., Ltd. +8,96% -19,05%
19/04 Betta Pharmaceuticals Co. présente ses résultats pour le premier trimestre clos le 31 mars 2024 CI
2023 Betta Pharmaceuticals Co. publie ses résultats pour les neuf mois se terminant le 30 septembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Beijing Mabworks Biotech Co., Ltd. announced that it expects to receive CNY 150.000042 million in funding from Betta Pharmaceuticals Co., Ltd.
C4 Therapeutics Shares Up 18% After Lung Cancer Drug Application Receives FDA Clearance
Betta Pharmaceuticals Gets Nod for Voronib Tablets' Listing
Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 15 June 2023
C4 Therapeutics, Betta Pharmaceuticals Sign Deal to Develop, Commercialize CFT8919 in Greater China
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC
C4 Therapeutics, Inc. announced that it expects to receive $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd. Approves Cash Dividend for the Year of 2022
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Betta Pharmaceuticals Co., Ltd. Announces Profit Distribution Proposal for 2022
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Betta Pharmaceuticals Gets Nod to Start Clinical Trial of Tumor Drug in China
Betta Pharmaceuticals Co., Ltd. cancelled the transaction announced on June 13, 2022
Betta Pharmaceuticals Co., Ltd. Approves Board Elections
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 300558
  4. Actualités Betta Pharmaceuticals Co., Ltd.
  5. Autres langues